The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCiusss de L'Est de l'Île de Montréal

About this trial

Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.

Eligibility criteria

Qualifiers

ASA 1-3

Laparascopic surgery (including general surgery, gynecology, urology) a small abdominal incision (less than 5 cm) will be tolerated.

Disqualifiers

Patient refusal

Chronic use of opioids

Allergy to medication used in the trial

Pregnant or breastfeeding women

Trial design

Treatments tested in this trial

  • Dexmedetomidine
  • Placebo

Treatment groups

72 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ciusss de L'Est de l'Île de Montréal

Lead sponsor

Maisonneuve-Rosemont Hospital

Sponsor institution